Immix Biopharma Inc

NASDAQ IMMX

Download Data

Immix Biopharma Inc Accounts Payable Turnover Ratio 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending March 31, 2024: 100.00%

Immix Biopharma Inc Accounts Payable Turnover Ratio 1 year YoY Change (%) is 100.00% for the Trailing 12 Months (TTM) ending March 31, 2024. The accounts payable turnover ratio measures the number of times a company pays off its accounts payable during a specific period. It is calculated by dividing the company's revenue by its accounts payable. This ratio indicates how efficiently a company manages its outstanding payments to suppliers and vendors. A higher turnover ratio suggests that the company is paying off its obligations quickly, while a lower ratio may indicate a slower payment process or potential liquidity issues. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
  • Immix Biopharma Inc Accounts Payable Turnover Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was -23.43, a 0.00% change year over year.
  • Immix Biopharma Inc Accounts Payable Turnover Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 0.00, a 0.00% change year over year.
  • Immix Biopharma Inc Accounts Payable Turnover Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was 0.00.
NASDAQ: IMMX

Immix Biopharma Inc

CEO Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.
IPO Date Dec. 16, 2021
Location United States
Headquarters 11400 West Olympic Boulevard, Los Angeles, CA, United States, 90064
Employees 14
Sector Healthcare
Industry Biotechnology
Description

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Similar companies

HEPA

Hepion Pharmaceuticals Inc

NA

NA

AVRO

AVROBIO Inc

NA

NA

FRLN

Freeline Therapeutics Holdings Plc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email